Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-TCR Summit Europe 2021 | CT053, anti-GPC3 CAR-T and targeting solid tumors

Hong Ma, MD, MSc, MBA, CARsgen Therapeutics, Shanghai, China, provides an overview of recent data obtained from a number of Phase I clinical trials evaluating CT053, a fully human B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory (R/R) multiple myeloma. Studies discussed include LUMMICAR-1 (NCT03975907), LUMMICAR-2 (NCT03915184) and an investigator-initiated program in eastern China (NCT03716856, NCT03302403 and NCT03380039). In addition, Dr Ma describes recent and ongoing studies evaluating anti-GPC3 CAR-T cell therapy in patients with hepatocellular carcinoma. He also discusses overcoming the major challenges associated with targeting solid tumors using CAR-T therapies. This interview took place during the CAR-TCR Summit Europe 2021.